Medical insurance prices for mavacamten

Mavacamten (mavacamten) is a new type of cardiac myosin inhibitor , mainly used to treat obstructive hypertrophic cardiomyopathy (HCM). The drug improves patients' cardiac function, especially left ventricular outflow tract (LVOT) obstruction, by selectively inhibiting myocardial contraction. Clinical studies have shown that Mavaceta can significantly reduce the LVOT gradient and improve patients' symptoms, including shortness of breath, chest pain and fatigue, thereby improving the quality of life. In addition, the drug reduces the need for space-reducing therapy (SRT) in patients, providing a new treatment option for patients who do not respond well to traditional drugs such as beta-blockers or calcium channel blockers.

The pharmacological mechanism of Mavaceta is achieved by regulating myocardial contractile function. This characteristic makes it effective in treating obstructive HCM.HCM. However, because this drug may cause a decrease in left ventricular ejection fraction (LVEF), its use needs to be strictly monitored by a physician. Currently, the drug is required to be obtained through the FDA's Risk Evaluation and Mitigation Strategy (REMS) program to ensure patient safety while taking the drug.

As for medical insurance prices, Mavakatai was launched in China in April 2024, and was included in the reimbursement scope of Class B medical insurance in November of the same year. Although the specific drug prices have not yet been clarified, under normal circumstances, the reimbursement ratio for Class B drugs is usually between 50% and 70%, which means that the individual costs borne by patients are expected to be reduced accordingly. The scope of application and reimbursement rates of medical insurance policies may vary from region to region, so patients should consult their local medical insurance agency or hospital to obtain the latest information and guidance before taking medication.

Reference materials:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00763-7/fulltext